MetLife Investment Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

MetLife Investment Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,723	Closed	-$155K	–	2356
2020 Q4	$155K	Buy	+6,723	New	+$85.2K	﹤0.01%	2113
2020 Q3	–	Sell	-7,148	Closed	-$107K	–	2349
2020 Q2	$107K	Hold	7,148	–	–	﹤0.01%	2225
2020 Q1	$87.1K	Buy	+7,148	New	+$114K	﹤0.01%	2150

MetLife Investment Management's PRVL Position: Q1 2021 in Review

MetLife Investment Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 6,723 shares — an estimated $155K sold.

MetLife Investment Management first reported a position in PRVL in Q1 2020 and held it in 3 quarters. The position peaked at $155K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

MetLife Investment Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
MetLife Investment Management sold 6,723 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $155K.
MetLife Investment Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q1 2020 and held it in 3 quarters.
MetLife Investment Management's Prevail Therapeutics Inc. Common Stock position peaked at $155K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on MetLife Investment Management's 13F filing for Q1 2021, filed 14 May 2021.